Simulations Plus, Inc (SLP) is slated to release first-quarter fiscal 2025 results on Jan. 7.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $18.7 million, which indicates growth of 28.9% from the year-ago quarter’s reported figure.The consensus mark for earnings is pegged at 18 cents per share, indicating increase of 80% from the prior-year levels. The company’s earnings have surpassed the Zacks Consensus ...

Simulations Plus (SLP) closed the last trading session at $32.74, gaining 6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $51.40 indicates a 57% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $9.76. While the lowest estimate of $39 indicates a 19.1% increase from the current price level, the most optimistic analyst expects ...

Core Viewpoint - Simulations Plus (SLP) experienced an 8.9% increase in share price, closing at $30.04, following a significant volume of trading, contrasting with an 18.8% decline over the previous four weeks [1] Financial Performance - The increase in share price is attributed to strong topline performance driven by synergies from acquisitions and organic growth, with new customer acquisitions and increased sales in the Software segment contributing positively [2] - In the last reported quarter, the company achieved an organic revenue growth of 14%, excluding a $2.3 million contribution from the Pro-ficiency acquisition [3] Revenue Projections - For fiscal 2025, Simulations Plus anticipates revenues between $90 million and $93 million, indicating a growth of 28-33% from fiscal 2024 revenues, with organic growth projected between 10% and 15% [4] - The Pro-ficiency acquisition is expected to add an additional $15 million to $18 million to revenues, enhancing the financial outlook [4] Grants and Collaborations - Simulations Plus secured a grant from the U.S. Food and Drug Administration to support the use of its GastroPlus software in pharmacokinetic modeling, in collaboration with the University of Connecticut's School of Pharmacy [5] Earnings Expectations - The company is projected to report quarterly earnings of $0.18 per share, reflecting an 80% year-over-year increase, with revenues expected to reach $18.69 million, up 28.9% from the previous year [6] - The consensus EPS estimate for the quarter has been revised 105.9% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [7] Industry Context - Simulations Plus operates within the Zacks Computer - Software industry, where Autodesk (ADSK) also resides, having closed 2.5% higher recently and showing a 7.5% return over the past month [7]

Shares of Simulations Plus (SLP) have gained 1.1% over the past four weeks to close the last trading session at $30.70, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $54.50 indicates a potential upside of 77.5%.The average comprises four short-term price targets ranging from a low of $47 to a high of $65, with a standard deviation of $7.94. While the lowest estimate indicates ...

Simulations Plus, Inc. (SLP) reported fourth-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 6 cents per share, which declined 66.7% year over year. The figure, however, beat the Zacks Consensus Estimate of 4 cents per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Quarterly revenues jumped 19% year over year to $18.7 million due to higher software and services revenues in the Clinical Pharmacology & Pharmacometrics (CPP), higher software ...

Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this maker of software used in pharmaceutical research would post earnings of $0.16 per share when it actually produced earnings of $0.19, delivering a surprise of 18.75%.Ov ...

Exhibit 99.1 S+ SimulationsPlus Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 LANCASTER, CA, October 23, 2024 – Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelli ...

Simulations Plus, Inc. (SLP) has streamlined its business unit and leadership structure to foster growth after recent acquisitions. These updates will be implemented on Aug 30, 2024. Over the past year, Simulations Plus made two major acquisitions, including the largest in its corporate history. In June 2024, the company acquired Pro-ficiency Holdings, Inc. and its subsidiaries from QHP Capital and its minority shareholders for about $100 million, expanding its footprint across the drug development continuu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended May 31, 2024 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ______ to ______ Commission file number: 001-32046 Simulations Plus, Inc. (Name of registrant as specified in its charter) (State or other jurisdiction of ...

Financial Data and Key Metrics Changes - Total revenue increased by 14% to $18.5 million in Q3 2024, with Software revenue up 12% and Services revenue up 18% [30][4] - Diluted earnings per share were $0.15 compared to $0.20 last year, while adjusted diluted earnings per share were $0.19 compared to $0.21 last year [33][14] - Total gross margin was 71%, down from 82% last year, with Software gross margin at 88% versus 91% and Services gross margin at 41% versus 63% [11][12] Business Line Data and Key Metrics Changes - Software segment revenues increased by 12% in Q3 and 14% for the nine-month period, driven by renewals and upsells [5] - Physiologically Based Pharmacokinetics (PBPK) business unit saw a 7% revenue increase in Q3 and 9% year-to-date, adding 14 new customers [6] - Quantitative Systems Pharmacology (QSP) business unit revenues surged by 80% in Q3 and 78% year-to-date, although quarterly results can be variable due to high license costs [7] - Services revenues in the Clinical Pharmacology & Pharmacometrics (CPP) business unit grew by 27% in Q3 and 16% year-to-date, while QSP services revenue grew by 49% in Q3 and 74% year-to-date [8] Market Data and Key Metrics Changes - The market funding environment for biotech is improving, with signs of recovery particularly for companies with drug candidates in clinical trials [25] - Customer renewal rates for the trailing 12 months were 92% based on fees and 84% based on accounts [12] Company Strategy and Development Direction - The company aims to achieve full-year revenue guidance of $69 million to $72 million, with year-over-year growth expected between 15% to 20% [17] - The acquisition of Pro-ficiency is expected to enhance the company's offerings and expand its total addressable market to $8 billion [36][29] - The company is focused on investing in growth initiatives rather than continuing its quarterly cash dividend [15] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding large pharmaceutical client spending, noting a mix of increased and conservative expenditures [25] - The company anticipates that the integration of Pro-ficiency will progress according to plan and is expected to contribute positively to fiscal year 2025 earnings [61][29] Other Important Information - Total operating expenses were 61% of revenue compared to 57% last year, primarily due to acquisition costs and increased compensation expenses [13] - The company ended the quarter with $119 million in cash and investments, remaining well-capitalized with no debt [34] Q&A Session Summary Question: What is the outlook for organic revenue growth in 2025? - Management indicated that the biosimulation market is growing at 12% to 15%, and they expect potential improvements in fiscal year 2025 [64] Question: Can you provide updates on Pro-ficiency's contribution? - The expected contribution from Pro-ficiency in fiscal year 2025 remains at $15 million to $18 million, with potential for better performance [65] Question: What factors impacted the adjusted EBITDA margin this quarter? - The adjusted EBITDA margin was impacted by costs associated with a significant software release and increased hiring expenses [66]